Residency · Residency · Physical Medicine Rehabilitation
Cerebral Palsy: Classification and Rehabilitation Management
Overview
Most common motor disability in childhood (prevalence: 2-3 per 1,000 live births). Group of permanent disorders of movement and posture caused by non-progressive disturbances in the developing fetal or infant brain. Motor impairment often accompanied by: epilepsy (25-45%), intellectual disability (30-50%), visual impairment (40%), hearing loss (10%), communication disorders, behavioral issues. NOT a progressive condition, but functional manifestations change with growth and aging. Lifelong condition requiring physiatric management from childhood through adulthood.
Etiology
Prenatal (80%): brain malformations, intrauterine infections (TORCH), maternal conditions, genetic factors, periventricular leukomalacia from placental insufficiency. Perinatal (10%): birth asphyxia, prematurity, intracranial hemorrhage (especially IVH Grade III-IV in preterm infants). Postnatal (10%): meningitis, encephalitis, traumatic brain injury, near-drowning, kernicterus.
Classification Systems
Topographic Classification
Hemiplegia/hemiparesis: one side affected (arm usually more than leg). Diplegia/diparesis: both lower extremities primarily affected (common in premature infants with PVL). Quadriplegia/quadriparesis: all four extremities affected (most severe motor involvement). Monoplegia: single limb (rare, often evolves into hemiplegia). Triplegia: three limbs (relatively rare designation).
Motor Type Classification
Spastic (70-80%): velocity-dependent increase in muscle tone, hyperreflexia, clonus. UMN pattern: corticospinal tract involvement. Most common type. Dyskinetic (10-15%): Dystonic: sustained, twisting postures, co-contraction. Choreoathetoid: involuntary, writhing movements. Basal ganglia involvement (often from kernicterus or asphyxia). Ataxic (5-10%): cerebellar involvement.
Impaired coordination, balance, intention tremor. Wide-based gait, dysmetria. Mixed: combination of types (commonly spastic + dyskinetic).
Gross Motor Function Classification System (GMFCS)
5-level classification based on self-initiated movement with emphasis on sitting, walking, and wheeled mobility. Age-dependent descriptions (0-2, 2-4, 4-6, 6-12, 12-18 years). Level I: walks without limitations; limitations in advanced motor skills (running, jumping). Level II: walks with limitations; difficulty with uneven surfaces, stairs without railing, long distances.
Level III: walks using hand-held mobility device (walker, crutches); may use wheelchair for long distances. Level IV: self-mobility with limitations; transported in manual wheelchair or uses power wheelchair. Level V: transported in manual wheelchair in all settings; severe limitations in head/trunk control. GMFCS level by age 2 is predictive of adult ambulatory status. Stable over time (does not improve with intervention).
| GMFCS Level | Mobility | Assistive Devices | Ambulatory Prognosis |
|---|---|---|---|
| I | Walks without limitations | None | Community ambulator |
| II | Walks with limitations | Railing for stairs | Community ambulator with difficulty |
| III | Walks with hand-held device | Walker, crutches | Household/limited community |
| IV | Limited self-mobility | Power wheelchair | Primarily wheelchair |
| V | Transported in all settings | Manual wheelchair (pushed) | Non-ambulatory |
<image>GMFCS levels I through V with illustrations showing functional mobility at each level</image>
Other Classification Systems
Manual Ability Classification System (MACS): hand function, 5 levels. Communication Function Classification System (CFCS): communication ability, 5 levels. Eating and Drinking Ability Classification System (EDACS): feeding, 5 levels.
Comprehensive Assessment
Motor Function Assessment
Gross Motor Function Measure (GMFM-66 or GMFM-88): standardized measure of gross motor abilities. GMFM-66 motor growth curves: predict functional ceiling by GMFCS level. GMFCS I-II: peak motor function at age 5-7. GMFCS III: peak at age 4-5.
GMFCS IV-V: peak at age 3-4. Functional plateau or decline can occur in adolescence/adulthood. Gait analysis (instrumented): guides surgical decision-making. Functional mobility assessment in home and community environments.
Musculoskeletal Assessment
Range of motion: monitor for progressive contractures. Common contractures: hip flexion, knee flexion, ankle equinus, wrist flexion. Hip surveillance: regular radiographic monitoring for hip displacement. Migration percentage (Reimers index): percentage of femoral head uncovered.
GMFCS IV-V: highest risk for hip displacement (60-90%). Surveillance schedule: every 6 months for GMFCS III-V until skeletal maturity. Scoliosis screening: especially GMFCS IV-V. Limb length discrepancy assessment.
Associated Conditions
Epilepsy management and seizure control. Visual assessment (cortical visual impairment, strabismus). Hearing screening. Cognitive and learning assessment.
Behavioral and psychiatric screening. Pain assessment (often underrecognized - up to 75% of children with CP experience pain). Nutritional status and growth (failure to thrive, obesity). Drooling assessment and management. Constipation.
Spasticity Management
Non-Pharmacologic
Stretching and positioning programs. Serial casting (progressive stretch into range). Orthotic management (AFOs, hand splints). Weight-bearing programs. Hippotherapy, aquatic therapy.
Pharmacologic - Oral Medications
Baclofen (oral): GABA-B agonist, sedation and tolerance limit efficacy. Diazepam: GABA-A agonist, sedation and dependence concerns. Tizanidine: alpha-2 agonist, less sedation than diazepam. Dantrolene: direct muscle relaxant, hepatotoxicity risk (monitor LFTs). Oral medications generally more useful for generalized spasticity.
Botulinum Toxin Injections
Focal spasticity management. OnabotulinumtoxinA or abobotulinumtoxinA. Common targets: gastrocnemius-soleus (equinus), hamstrings, hip adductors, biceps, pronator teres. Onset: 3-7 days; Duration: 3-6 months.
Combined with stretching, casting, orthotics, and therapy for optimal results. Dosing: 10-20 units/kg total body dose (onabotulinumtoxinA). Guidance: EMG, electrical stimulation, or ultrasound for accurate muscle localization.
Intrathecal Baclofen (ITB) Therapy
Programmable pump delivers baclofen directly to intrathecal space. 100-1000x less dose than oral (minimizes systemic side effects). Indications: generalized spasticity GMFCS III-V, failed oral medications. Trial via lumbar puncture before permanent implant.
Complications: catheter malfunction, infection, baclofen withdrawal (life-threatening - fever, seizures, rhabdomyolysis). Requires lifelong management and regular pump refills.
Selective Dorsal Rhizotomy (SDR)
Surgical sectioning of selected dorsal (sensory) nerve rootlets (L1-S2). Permanent reduction in spasticity. Best candidates: GMFCS II-III, spastic diplegia, good selective motor control, adequate strength. Requires intensive post-operative rehabilitation (12-18 months). Long-term outcomes: improved gait quality, reduced need for orthopedic surgery.
<image>Spasticity management options in cerebral palsy showing escalating interventions from conservative to surgical</image>
Orthotic Management
AFOs (ankle-foot orthoses): most commonly prescribed. Solid AFO: maximum control, prevents equinus and crouch. Hinged AFO: allows dorsiflexion, prevents plantarflexion (free or adjustable). Ground reaction AFO: prevents crouch gait (knee extension moment).
Posterior leaf spring (PLS): flexible, assists toe clearance in swing. KAFOs: for significant knee instability or extensor weakness. Upper extremity orthoses: wrist cock-up splints, thumb abduction splints, neoprene thumb wraps. Spinal orthoses: for scoliosis management (limited evidence for preventing progression in neuromuscular scoliosis).
Orthopedic Surgery
Goal: correct musculoskeletal deformities to improve function and prevent deterioration. Single-event multilevel surgery (SEMLS): correcting multiple deformities in one surgical procedure. Reduces total number of surgeries and rehabilitation episodes. Requires instrumented gait analysis for planning.
Common procedures: Gastrocnemius/Achilles lengthening (equinus). Hamstring lengthening (crouch gait). Adductor release/transfer (scissoring, hip at risk).
Femoral derotation osteotomy (internal rotation gait). Hip reconstruction (subluxation/dislocation). Scoliosis fusion (neuromuscular scoliosis GMFCS IV-V).
Transition to Adult Care
Planning should begin at age 14-16. Address: vocational planning, independent living skills, sexuality/reproductive health, transportation, financial/legal considerations (guardianship). Adult physiatrist should assume ongoing management. Functional decline in adulthood: pain, fatigue, decreasing mobility common by 30s-40s.
Chronic musculoskeletal overuse: shoulder pain from wheelchair use, cervical myelopathy in dyskinesia. Ongoing need for spasticity management, orthotic prescription, equipment maintenance. Mental health screening: depression and anxiety rates increased in adults with CP.
Clinical Pearls
GMFCS level at age 2 predicts lifelong ambulatory potential - GMFCS I-III will walk, GMFCS IV-V will use wheelchairs as primary mobility. Hip surveillance with regular radiographs is essential for GMFCS III-V children - hip displacement is preventable with early detection and intervention. GMFM-66 motor growth curves show that most children with CP reach their peak motor function by age 5-7, followed by plateau or decline - set realistic expectations with families. Botulinum toxin injections without concurrent therapy, stretching, and orthotics will fail - the injection creates a window of opportunity that must be leveraged with rehabilitation. Pain is present in up to 75% of children with CP but is frequently underrecognized and undertreated - always ask about pain and use appropriate assessment tools for nonverbal patients.
<image>Hip surveillance protocol for cerebral palsy showing migration percentage measurement and intervention thresholds by GMFCS level</image>
References
- Rosenbaum P, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8-14.
- Palisano R, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214-223.
- Novak I, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885-910.
- Hanna SE, et al. Stability and decline in gross motor function among children and youth with cerebral palsy. Dev Med Child Neurol. 2009;51(4):295-302.
- Graham HK, et al. Cerebral palsy. Nat Rev Dis Primers. 2016;2:15082.
